美女免费一级视频在线观看

Novo Nordisk’s head of U.S. marketing, Ulrich Otte, is no longer in the role and is exploring other internal opportunities at the company outside of the U.S.

Otte, who has served as SVP of marketing and patient solutions since February, will be replaced by Dave Moore, EVP, U.S. operations as interim lead until a successor is identified, a Novo Nordisk spokesperson told MM+M.

MM+M was notified of the leadership change on Wednesday, the day Novo Nordisk released its Q2 earnings report. 

While sales of the company’s popular GLP-1 drug Wegovy jumped 67% in the second quarter, Novo cut its full-year guidance citing “lower growth expectations” for Ozempic and Wegovy for the rest of 2025. The company pointed to the widespread use of compounded GLP-1s as being a main factor, as well as “slower-than-expected” market expansion.

As part of its restructuring in the face of those headwinds, Novo announced its CEO Lars Fruergaard Jørgensen would be stepping down, and Maziar Mike Doustdar will replace him as the new CEO, effective this week.

Novo made the decision about Jørgensen in May amid mounting concerns around declining shares and the company losing its edge to its main competitor, Eli Lilly, in the obesity market. After reaching a record high in June 2024, Novo’s shares have dropped by more than 50% as the Danish drugmaker increasingly faces competition from Lilly, compounders and a flush of other obesity players entering the market.

But the closely-watched race shifted again Thursday, when Lilly released its most recent data on its daily obesity pill, showing that orforglipron led to 11.2% weight loss — a disappointing result. Lilly’s shares dropped by 13% after the news, while Novo’s shares increased by 7%.

In Novo’s earnings report statement, Jørgensen said “we are taking measures to sharpen our commercial execution further, and ensure efficiencies in our cost base while continuing to invest in future growth.” Jørgensen has mentioned in interviews that layoffs might be expected, according to Reuters.

Novo’s U.S. marketing arm appears to be undergoing its own leadership shuffle, with the company noting that Moore will have direct oversight of the Marketing and Patient Solutions organization until a new leader is appointed. Moore has held various roles in marketing, sales and commercial operations at Novo Nordisk, and previously worked at Roivant Sciences, Cempra Pharmaceuticals, Tranzyme Pharma and Johnson & Johnson.

Otte has spent 25 years at Novo Nordisk, according to his LinkedIn, starting in 2000 in Copenhagen. He has held various roles at the company, including SVP, finance & operations before serving as SVP of Marketing & Patient Solutions at the company’s Princeton, New Jersey location.

Liz Skrbkova, senior director of media and stakeholder relations at Novo Nordisk, confirmed the leadership change was effective July 30.

“We have a well-defined strategy, a robust product portfolio, and a highly experienced leadership team globally and in the U.S.,” Skrbkova said. She added that Doustdar “brings a strong sense of urgency and a laser focus on performance, aimed at delivering innovation to the patients we serve.”

Over the past several years, Novo Nordisk has taken a defensive approach to the compounded GLP-1s issue, including launching a series of ads aimed at underscoring safety and quality risks around compounded drugs.

In February, it rolled out its “Check before you inject” campaign in response to telehealth company Hims & Hers’ controversial Super Bowl ad. Novo ultimately ended its short-lived partnership with Hims & Hers in June, claiming the platform employed “deceptive” marketing around compounded GLP-1s under the guise of “personalization.”

This story has been updated to include a statement from Novo Nordisk.